Moreover, concurring that “cancer stem cells are the leading power behind tumor growth, with the ability of self-renewal, metastasis, and resistance to conventional chemotherapy” (39), our data showing that MED10 is co-overexpressed with stemness markers CD44, SOX2, PROM1/CD133, KLF4, NANOG, and LIN28A in patients with urothelial recurrence and concomitantly upregulated with NANOG and CD44 in patients with local recurrence, but profoundly suppressed, akin to the other stemness/pluripotency markers, in patients with non-recurrent disease, are also clinically relevant. This evidence concerns the gene KLF4 and cancer.